Metabolic Symbiosis-Blocking Nano-Combination for Tumor Vascular Normalization Treatment

Area of Science:

• Oncology
• Nanomedicine
• Cancer Metabolism

Background:

• Clinical tumor vascular normalization treatment (TVNT) using anti-vascular endothelial growth factor (anti-VEGF) drugs and metronomic chemotherapy (MET) faces antagonism from tumor microenvironment metabolic cross-talk.
• Metabolic interactions between tumor cells and endothelial cells (ECs) hinder the effectiveness of current TVNT strategies.

Purpose of the Study:

• To develop a novel nano-combination therapy to overcome the metabolic antagonism in the tumor microenvironment.
• To enhance the efficacy of tumor vascular normalization and achieve significant antitumor effects.

Main Methods:

• Preparation of a nano-combination drug integrating EC-targeted glycolysis inhibition and tumor cell glycolysis inhibition.
• Co-administration of the nano-combination drug with anti-VEGF and MET therapies.
• Analysis of pathways related to angiogenesis, tumor cell proliferation, and immunosuppression.
• Evaluation of the sugar-lipid-protein metabolism balance within the tumor microenvironment.

Main Results:

• The nano-combination therapy successfully normalized tumor vasculature, creating a stronger and more lasting vascular network.
• Significant improvements in antitumor efficacy were observed.
• A positive feedback loop was established between TVNT and anti-tumor therapy.
• The negative metabolic balance in the tumor microenvironment was effectively broken.

Conclusions:

• The developed nano-combination strategy offers a promising approach to overcome the limitations of clinical TVNT.
• This study provides a new insight for improving cancer treatment by addressing metabolic cross-talk in the tumor microenvironment.